Phase 1 Study of VEGF Trap (Aflibercept) Administered Subcutaneously to Patients with Advanced Solid Tumors

PURPOSE: To determine the maximum tolerated dose (MTD) or maximal administered dose (MAD) and pharmacokinetic and safety profiles of subcutaneously administered VEGF Trap (aflibercept), a novel anti-angiogenic agent. EXPERIMENTAL DESIGN: In this open-label, dose-escalation study, patients with advan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tew, William P., Gordon, Michael, Murren, John, Dupont, Jakob, Pezzulli, Sandra, Aghajanian, Carol, Sabbatini, Paul, Mendelson, David, Schwartz, Lawrence, Gettinger, Scott, Psyrri, Amanda, Cedarbaum, Jesse M., Spriggs, David R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4211604/
https://ncbi.nlm.nih.gov/pubmed/20028764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-2103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados